Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs

References

• Zhou Y, You MJ, Young KH, et al. Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol. 2012;43:1347–1362.
   PubMed Web of Science ®Google Scholar
• Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133–143.
   PubMed Web of Science ®Google Scholar
• Lin HY, Chen CS, Lin SP, et al. Targeting histone deacetylase in cancer therapy. Med Res Rev. 2006;26:397–413.
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–692.
   PubMed Web of Science ®Google Scholar
• Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280:233–241.
   PubMed Web of Science ®Google Scholar
• Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 2000;60:4561–4572.
   PubMed Web of Science ®Google Scholar
• Li G, Margueron R, Hu G, et al. Highly compacted chromatin formed in vitro reflects the dynamics of transcription activation in vivo. Mol Cell. 2010;38:41–53.
   PubMed Web of Science ®Google Scholar
• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19–25.
   PubMed Web of Science ®Google Scholar
• Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116:3013–3022.
   PubMed Web of Science ®Google Scholar
• Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2007;16:659–678.
   PubMed Web of Science ®Google Scholar
• Shao Y, Gao Z, Marks PA, et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2004;101:18030–18035.
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13–18.
   PubMed Web of Science ®Google Scholar
• Shao W, Growney J, Feng Y, et al. Potent anticancer activity of a pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models. Cancer Res. 2008;68:735.
   Google Scholar
• Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14:4500–4510.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–1206.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther. 2007;6:64–69.
   PubMed Web of Science ®Google Scholar
• Kubo M, Kanaya N, Petrossian K, et al. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat. 2013;137:93–107.
   PubMed Web of Science ®Google Scholar
• Zang H, Qian G, Zong D, et al. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer. 2020;126:2024–2033.
   PubMed Web of Science ®Google Scholar
• Maiso P, Colado E, Ocio EM, et al. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia. 2009;23:2265–2274.
   PubMed Web of Science ®Google Scholar
• Tan P, Wei A, Mithraprabhu S, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4:e170.
   PubMed Web of Science ®Google Scholar
• Bashash D, Safaroghli-Azar A, Bayati S, et al. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: shedding new light on resistance to aprepitant. Int J Biochem Cell Biol. 2018;103:105–114.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Wu J, Cang S, Liu C, et al. Development of human prostate cancer stem cells involves epigenomic alteration and PI3K/AKT pathway activation. Exp Hematol Oncol. 2020;9:1–6.
   PubMed Web of Science ®Google Scholar
• Yang Q, Jiang W, Hou P. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112–124.
   PubMed Web of Science ®Google Scholar
• Mehrpouri M, Safaroghli-Azar A, Momeny M, et al. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity. Eur J Pharmacol. 2020; 875:173050.
   PubMed Web of Science ®Google Scholar
• Alipour F, Riyahi N, Safaroghli-Azar A, et al. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO). Int J Biochem Cell Biol. 2019;116:105615.
   PubMed Web of Science ®Google Scholar
• Bashash D, Safaroghli-Azar A, Dadashi M, et al. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: shedding new light on resistance to Idelalisib. Int J Biochem Cell Biol. 2017;85:149–158.
   PubMed Web of Science ®Google Scholar
• Bashash D, Delshad M, Riyahi N, et al. Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: proposing novel therapeutic potential for BKM120. Eur J Pharmacol. 2018;841:10–18.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Ramaswamy S, Vazquez F, et al. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000;20:8969–8982.
   PubMed Web of Science ®Google Scholar
• Burke MJ, Bhatla T. Epigenetic modifications in pediatric acute lymphoblastic leukemia. Front Pediatr. 2014;2:42.
   PubMed Web of Science ®Google Scholar
• Neri LM, Cani A, Martelli A, et al. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 2014;28:739–748.
   PubMed Web of Science ®Google Scholar
• Mosleh M, Safaroghli-Azar A, Bashash D. Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-induced resistance. Int J Biochem Cell Biol. 2020; 122:105734.
   PubMed Web of Science ®Google Scholar
• Steelman L, Pohnert S, Shelton J, et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18:189–218.
   PubMed Web of Science ®Google Scholar
• Bertacchini J, Guida M, Accordi B, et al. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia. 2014;28:2197–2205.
   PubMed Web of Science ®Google Scholar
• Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol. 2002;250:1–23.
   PubMed Web of Science ®Google Scholar
• Bashash D, Safaroghli-Azar A, Delshad M, et al. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: shedding new light on NVP-BKM120 mechanism of action. Int J Biochem Cell Biol. 2016;79:308–317.
   PubMed Web of Science ®Google Scholar
• Safaroghli-Azar A, Bashash D, Sadreazami P, et al. PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells. Anticancer Drugs. 2017;28:436–445.
   PubMed Web of Science ®Google Scholar
• Yang L, Yang G, Ding Y, et al. Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. Oncol Rep. 2018;40:479–487.
   PubMed Web of Science ®Google Scholar
• Amati B, Littlewood T, Evan G, et al. The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. Embo J. 1993;12:5083–5087.
   PubMed Web of Science ®Google Scholar
• Chandramohan V, Jeay S, Pianetti S, et al. Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels. J Immunol. 2004;172:5522–5527.
   PubMed Web of Science ®Google Scholar
• Sheikh ‐Zeineddini N, Bashash D, Safaroghli-Azar A, et al. Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells. J Cell Biochem. 2019;120:14004–14016.
   PubMed Web of Science ®Google Scholar
• Sayyadi M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, et al. c-Myc inhibition using 10058-F4 increased the sensitivity of acute promyelocytic leukemia cells to arsenic trioxide via blunting PI3K/NF-κB axis. Arch Med Res. 2020;51:636–644.
   PubMed Web of Science ®Google Scholar